We are live on ! Find out more
TERN

Terns Pharmaceuticals

Delisted

TERN was delisted on the 4th of May, 2026.

34 hedge funds and large institutions have $174M invested in Terns Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 17 increasing their positions, 7 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

143% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 7

0.41% more ownership

Funds ownership: 66.14%66.55% (+0.41%)

6% less funds holding

Funds holding: 3634 (-2)

14% less capital invested

Capital invested by funds: $204M → $174M (-$29.4M)

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

Holders
34
Holders Change
-2
Holders Change %
-5.56%
% of All Funds
0.6%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
17
Reduced
7
Closed
5
Calls
Puts
Net Calls
Net Calls Change

TERN Hedge Fund Activity: Q3 2021 in Review

34 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Terns Pharmaceuticals (TERN) for Q3 2021, worth a combined $174M — down 14% from $204M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of TERN and 3 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 17 added.

The largest buyer was BlackRock, adding an estimated $1.71M. The largest seller was Matthews International Capital Management, cutting an estimated $2.04M.

  • 34 institutional investors held Terns Pharmaceuticals (TERN) as of Q3 2021, down from 36 in Q2 2021.
  • Funds reported $174M of Terns Pharmaceuticals stock for Q3 2021, down 14% quarter-over-quarter.
  • 3 funds opened new Terns Pharmaceuticals positions in Q3 2021 and 5 closed out, a net change of -2 holders.
  • The largest Terns Pharmaceuticals buyer in Q3 2021 was BlackRock, an estimated $1.71M added.
  • The largest Terns Pharmaceuticals seller in Q3 2021 was Matthews International Capital Management, an estimated $2.04M sold.

Based on aggregated 13F filings for Q3 2021.